Rodents show apparent sex differences in their sexual behaviours. The present study used Kiss1 knockout (KO) rats to evaluate the role of kisspeptin in the defeminisation/masculinisation of the brain mechanism that controls sexual behaviours. Castrated adult Kiss1 KO males treated with testosterone showed no male sexual behaviours but demonstrated the oestrogen-induced lordosis behaviours found in wild-type females. The sizes of some of the sexual dimorphic nuclei of Kiss1 KO male rats are similar to those of females. Plasma testosterone levels at embryonic day 18 and postnatal day 0 (PND0) in Kiss1 KO males were high, similar to wild-type males, indicating that perinatal testosterone is secreted in a kisspeptin-independent manner. Long-term exposure to testosterone from peripubertal to adult periods restored mounts and intromissions in KO males, suggesting that kisspeptin-dependent peripubertal testosterone secretion is required to masculinise the brain mechanism. This long-term testosterone treatment failed to abolish lordosis behaviours in KO males, whereas kisspeptin replacement at PND0 reduced lordosis quotients in Kiss1 KO males but not in KO females. These results suggest that kisspeptin itself is required to defeminise behaviour in the perinatal period, in cooperation with testosterone. Oestradiol benzoate treatment at PND0 suppressed lordosis quotients in Kiss1 KO rats, indicating that the mechanisms downstream of oestradiol work properly in the absence of kisspeptin. There was no significant difference in aromatase gene expression in the whole hypothalamus between Kiss1 KO and wild-type male rats at PND0. Taken together, the present study demonstrates that both perinatal kisspeptin and kisspeptin-independent testosterone are required for defeminisation of the brain, whereas kisspeptin-dependent testosterone during peripuberty to adulthood is needed for masculinisation of the brain in male rats.
The tumor suppressor protein p53 (TP53) has many functions in cell cycle
regulation, apoptosis, and DNA damage repair, and is also involved in
spermatogenesis in the mouse. To evaluate the role of p53 in spermatogenesis in
the rat, we characterized testis biology in adult males of a novel p53 knockout
rat (SD-Tp53tm1sage). p53 knockout rats exhibited
variable levels of testicular atrophy, including significantly decreased testis
weights, atrophic seminiferous tubules, decreased seminiferous tubule diameter,
and elevated spermatocyte TUNEL labeling rates, indicating a dysfunction in
spermatogenesis. Phosphorylated histone H2AX protein levels and distribution
were similar in the non-atrophic seminiferous tubules of both genotypes, showing
evidence of pre-synaptic DNA double-strand breaks in leptotene and zygotene
spermatocytes, preceding cell death in p53 knockout rat testes. Quantification
of the spermatogonial stem cell (SSC) proliferation rate with bromodeoxyuridine
(BrdU) labeling, in addition to staining with the undifferentiated type A
spermatogonial marker GDNF family receptor alpha-1 (GFRA1), indicated that the
undifferentiated spermatogonial population was normal in p53 knockout rats.
Following exposure to 0.5 or 5 Gy X-ray, p53 knockout rats exhibited no germ
cell apoptotic response beyond their un-irradiated phenotype, while germ cell
death in wild-type rat testes was elevated to a level similar to the unexposed
p53 knockout rats. This study indicates that seminiferous tubule atrophy occurs
following spontaneous, elevated levels of spermatocyte death in the p53 knockout
rat. This phenomenon is variable across individual rats. These results indicate
a critical role for p53 in rat germ cell survival and spermatogenesis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.